Holen Sie sich die Stockscreener-App
6.46
6.90%
0.37
Aligos Therapeutics Inc Aktie (ALGS) Neueste Nachrichten
Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026 - Investing News Network
Biotech Aligos will post first-quarter results after markets close May 7 - Stock Titan
[ARS] Aligos Therapeutics, Inc. SEC Filing - Stock Titan
Aligos Therapeutics says China pact puts HBV drug in focus amid trial updates - MSN
Aligos Therapeutics (Nasdaq: ALGS) details ESPP, auditor and pay votes - Stock Titan
Aligos’ licensing deal in China broadens trial scope, secures immediate $25m - MLex
Is Aligos (ALGS) overbought or oversold? (Drifts Higher) 2026-04-27Retail Flow - Newser
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
This micro cap biotech stock is tracking its biggest intraday gains in 11 months – here’s why a China deal has retail buzzing - MSN
(ALGS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aligos Therapeutics (ALGS) Gets a Buy from H.C. Wainwright - The Globe and Mail
New Aligos hires get stock options for 10,700 shares under Nasdaq rule - Stock Titan
Aligos Therapeutics jumps on China licensing agreement - MSN
Aligos (ALGS) Stock: Why Margin Improvement (Institutional Demand) 2026-04-22Short Term Trading - Cổng thông tin điện tử tỉnh Tây Ninh
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop - TipRanks
Aligos Therapeutics (NASDAQ: ALGS) signs Hep B deal with up to $420M milestones - Stock Titan
Aligos (ALGS) Stock Volume Confirmation (Wavering) 2026-04-20Earnings Season - Cổng thông tin điện tử tỉnh Lào Cai
10 Health Care Stocks Moving In Friday's Intraday Session - Sahm
H.C. Wainwright reiterates Aligos stock rating on China deal - Investing.com UK
Aligos strikes license deal with Amoytop for HBV therapy development - The Pharma Letter
This drugmaker was about to run out of cash, but a Chinese partner came to the rescue - The Business Journals
H.C. Wainwright reiterates Aligos stock rating on China deal By Investing.com - Investing.com Canada
Aligos and Xiamen Amoytop sign deal for HBV therapy - Yahoo Finance
Aligos licenses hepatitis B drug to Amoytop for $25m upfront - Investing.com India
Aligos Therapeutics Says China Pact Puts HBV Drug In Focus Amid Trial Updates - Sahm
Jefferies reiterates Aligos Therapeutics stock rating on China deal By Investing.com - Investing.com South Africa
Jefferies reiterates Aligos Therapeutics stock rating on China deal - Investing.com
Aligos licenses hepatitis B drug to Amoytop for $25m upfront By Investing.com - Investing.com South Africa
Aligos Therapeutics Licenses Hepatitis B Drug to Xiamen Amoytop for Greater China - National Today
Aligos Therapeutics (ALGS) Secures Licensing Deal for Hepatitis B Treatment - GuruFocus
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Aligos Therapeutics stock surges on China licensing deal - Investing.com
Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection - Investing News Network
Aligos Therapeutics stock surges on China licensing deal By Investing.com - Investing.com Canada
Aligos Therapeutics jumps 22% on Greater China deal for Hepatitis B drug (ALGS:NASDAQ) - Seeking Alpha
More than 90 million live with HBV in Greater China; Aligos signs deal - Stock Titan
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Sahm
Hepatitis B: Updates from Aligos Therapeutics, Arbutus Biopharma Corporation and Precision BioSciences - European AIDS Treatment Group
0.83%
2.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):